Daiichi Sankyo (TSE:4568, Financial) rose during the quarter as the company sold its investment in Indian pharmaceutical company Sun Pharma, thus fully exiting its exposure to struggling Indian pharmaceutical business Ranbaxy.
From Brandes Global Equity Fund second quarter 2015 commentary.